Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

DBV Technologies S.A. (DBVT)

7.86   -0.2 (-2.48%) 10-17 16:00
Open: 8.01 Pre. Close: 8.06
High: 8.05 Low: 7.75
Volume: 496,697 Market Cap: 728M
DBV Technologies SA is a biopharmaceutical company. It is engaged in research and development of patient-friendly therapy for food and pediatric allergy patients.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 8.055 - 8.096 8.096 - 8.127
Low: 7.656 - 7.698 7.698 - 7.731
Close: 7.792 - 7.864 7.864 - 7.919

Technical analysis

as of: 2019-10-17 4:26:15 PM
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 10.53     One year: 12.25
Support: Support1: 6.63    Support2: 5.52
Resistance: Resistance1: 9.02    Resistance2: 10.49
Pivot: 7.89
Moving Average: MA(5): 7.48     MA(20): 8.19
MA(100): 9.09     MA(250): 9.92
MACD: MACD(12,26): -0.48     Signal(9): -0.48
Stochastic oscillator: %K(14,3): 31.61     %D(3): 23.32
RSI: RSI(14): 44.29
52-week: High: 20.10  Low: 3.60  Change(%): -58.8
Average Vol(K): 3-Month: 31230  10-Days: 98272

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.
DBVT has closed above bottom band by 48.9%. Bollinger Bands are 71.6% wider than normal. The large width of the bands suggest high volatility as compared to DBVT's normal range. The bands have been in this wide range for 6 bars. This is a sign that the current trend might continue.

Headline News

Analyst: DBV's Peanut Allergy Drug Could Outscore Aimmune's On Safety Front
Aimmune Therapeutics Inc (NASDAQ: AIMT )'s peanut allergy product candidate Palforzia to treat peanut allergy in children and adolescents has received the backing of an FDA panel that reviewed the NDA. Following the positive verdict, H.C. Wainwright looked at what the decision means for DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT ), which has a competing drug in late-stage development. The Analyst Andrew Fein reiterated a Buy rating on DBV with a $25 price target. The Thesis Friday's Adcom meeting validated safety concerns over Aimmune's AR101 treatment, with its peanut protein exposure possibly resulting in anaphylaxis reactions during therapy, Fein said in a Monday note. (See his track record here .) Anaphylaxis is a serious allergic reaction that occurs quickly and could cause death. The point about anaphylaxis arising from AR101 treatment that could necessitate epinephrine treatment could … Full story available on

DBV Resubmits Regulatory Application For Peanut Allergy Drug, Stock Rallies
Shares of small-cap biopharma company DBV TECHNOLOGIE/S ADR (NASDAQ: DBVT ) were advancing strongly Thursday in reaction to an announcement regarding a regulatory filing for its lead product candidate. What Happened DBV said late Wednesday it has submitted its Biologic License Application, or BLA, for Viaskin Peanut, which is being evaluated for treating peanut-allergic children ages 4-11. Viaskin Peanut, an epicutaneous immunotherapy, is DBV's proprietary investigational platform designed to leverage the skin to activate the immune system and induce desensitization to allergens. In December 2018, the company voluntarily withdrew … Full story available on

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 72.24
Shares Float (M) 44.53
% Held by Insiders
% Held by Institutions 46.27
Shares Short (K) 4370
Shares Short P. Month (K)

Stock Financials

EPS -3.270
Book Value (p.s.) 3.980
PEG Ratio
Profit Margin
Operating Margin
Return on Assets (ttm) -49.2
Return on Equity (ttm) -108.2
Qtrly Rev. Growth 2.2
Gross Profit (p.s.) 0.155
Sales Per Share
EBITDA (p.s.)
Qtrly Earnings Growth
Operating Cash Flow (M)
Levered Free Cash Flow (M)

Stock Valuations

P/E -2.40
P/E Growth Ratio -0.02
P/BV 1.97

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.